Melanoma News and Research

Latest Melanoma News and Research

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Polaris Group announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.

8 Apr 2011

Protecting skin from sun's ultraviolet radiation is best way to avoid potential skin problems

Summertime means plenty of fun in the sun for many. "I would burn on Saturday and Sunday, peel by Wednesday and be back on the water by the next Saturday doing the same thing," says Thomas Randall, a man in his 70s who spent much of his youth at a lake or a beach trying to tan a pale complexion. But countless hours of sun exposure have taken a toll on his skin, and he now needs regular examinations to search for pre-cancerous moles.

7 Apr 2011

Parkinson's disease linked to increased risk of prostate cancer

University of Utah School of Medicine researchers have found compelling evidence that Parkinson's disease is associated with an increased risk of prostate cancer and melanoma, and that this increased cancer risk also extends to close and distant relatives of individuals with Parkinson's disease.

7 Apr 2011

Combination of molecularly targeted cancer drug and anti-malarial drug stops tumor growth

Researchers at the University of Pennsylvania School of Medicine may have found a way to turn an adaptive cellular response into a liability for cancer cells. When normal cells are starved for food, they chew up existing proteins and membranes to stay alive. Cancer cells have corrupted that process, called autophagy, using it to survive when they run out of nutrients and to evade death after damage from chemotherapy and other sources.

6 Apr 2011

More than 900 young Britons diagnosed with the deadliest form of skin cancer each year

Each day more than two people under 35 in Britain are diagnosed with malignant melanoma - the deadliest form of skin cancer - according to new figures from Cancer Research UK.

6 Apr 2011

Zebrafish research suggests new drug targets and markers to help treat melanoma

Thanks to the zebrafish, there is new hope for people with melanoma, an aggressive skin cancer that is responsible for approximately 8,700 deaths each year in the United States.

5 Apr 2011

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene,a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that new data from Phase 1 and 2 clinical studies of JX-594 were presented in an oral presentation at the 46th Annual Meeting of the European Association for the Study of the Liver over the weekend at the Internationales Congress Centrum in Berlin, Germany.

5 Apr 2011

New computer-based system can distinguish similar secondary tumours

A new computer-based system discussed in the International Journal of Healthcare Technology and Management can distinguish between apparently similar secondary tumours and allow a cancer specialist to trace the metastases back to the site of the original cancer in the patient's body.

5 Apr 2011

Daiichi Sankyo acquires Plexxikon

Plexxikon Inc. today announced that its acquisition by Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company, has been successfully completed. Clearance under the Hart Scott Rodino Antitrust Improvements Act has been received. Under the terms of the deal, Plexxikon shareholders will receive $805 million up-front, with near-term milestone payments associated with the approval of PLX4032 totaling an additional $130 million.

4 Apr 2011

Positive results from GDC-0973, GDC-0941 combination therapy Phase I trial against cancer

The combination of two compounds that inhibit two of the most frequently mutated cancer pathways is showing promise in an ongoing Phase I trial, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

4 Apr 2011

Life Technologies launches new TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the launch of its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools with the precision to detect a single mutant molecule hiding in a background of 1 million normal copies.

4 Apr 2011

Cancer Commons researchers publish MDMM paper in PLoS ONE journal

Cancer Commons, an initiative of CollabRx, a provider of information technology to personalize cancer treatments and accelerate research, announces the publication of a molecular disease model of melanoma which classifies the disease into molecular subtypes, rather than traditional histological or cellular subtypes, and describes treatment guidelines for each subtype, including specific assays, drugs, and clinical trials.

31 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

MRF: FDA's decision on Yervoy offers new treatment options for patients with melanoma

Thirteen years of waiting is now over for melanoma patients. That's how long it's been since the last therapy became available to treat the most lethal form of skin cancer – melanoma. The FDA today announced approval of Yervoy, an immunotherapy treatment for advanced melanoma.

28 Mar 2011

U.S. FDA approves Yervoy to treat patients with late-stage melanoma

The U.S. Food and Drug Administration today approved Yervoy to treat patients with late-stage melanoma, the most dangerous type of skin cancer.

28 Mar 2011

ALCMI launches new CASTLE study to treat lung cancer

The Addario Lung Cancer Medical Institute today announced the enrollment of the initial subjects into its inaugural clinical trial known as CASTLE, targeting 250 subjects over two years among academic and community medical centers in the United States.

28 Mar 2011

FDA approves ipilimumab for metastatic melanoma treatment

The U.S. Food and Drug Administration announced today its approval of a new treatment for advanced melanoma, the deadliest and most difficult-to-treat form of skin cancer.

28 Mar 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

Plasmid containing Sindbis replicase genes can destruct lung cancer

Alpha viruses, such as Sindbis virus, carry their genetic information on a single strand of RNA. On infection they use a protein, replicase, to produce double stranded RNA which is used as genetic material to make more viruses. However the body recognizes dsRNA as foreign, and infected cells initiate an immune response.

28 Mar 2011

FDA approves ipilimumab to treat metastatic melanoma

The US Food and Drug Administration announced today that the drug ipilimumab has been approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.

28 Mar 2011